Letrozole (trade name Femera)

Views 1501
Download the GMI DOC on this Topic

Sign in to Purchase/Download Documents

Sign in / Register

Focus Your Research

Click any topic below to filter + focus research
19 Diseases Researched for Letrozole (trade name Femera)
NameACCKFocus
Drug-Induced Toxicity 432Locked
Breast Cancer330Locked
Musculoskeletal Abnormalities330Locked
Arthralgia110Locked
Arthritis110Locked
Bone Diseases110Locked
Breast Cancer: Recovery 110Locked
Children: Impaired Growth110Locked
HPA Axis Dysregulation110Locked
Insulin-like Growth Factor (IGF): Elevated110Locked
Myalgias110Locked
Osteoporosis110Locked
Polymyalgia Rheumatica110Locked
Prostatic Hyperplasia: Benign110Locked
Tendinitis110Locked
Birth Defects24Locked
Polycystic Ovary Syndrome24Locked
Prenatal Chemical Exposures24Locked
Abortion: Spontaneous12Locked
5 Adverse Pharmacological Actions Researched for Letrozole (trade name Femera)
NameACCKFocus
Carcinogenic110Locked
Endocrine Disruptor110Locked
Endocrine Disruptor: Pituitary110Locked
Embryotoxic24Locked
Teratogenic24Locked
Related Topics

Letrozole (trade name Femera) is a Sub of the following Topic

View the Evidence:
12 Abstracts with Letrozole (trade name Femera) Research

[+]

Arimidex therapy contributes in the decline of bone mineral density in early breast cancer patients.Jan 01, 2010

Pubmed Data : Bratisl Lek Listy. 2010;111(1):27-32. PMID: 20429308
Article Published Date : Jan 01, 2010
Study Type : Human Study
Additional Links
Diseases : Breast Cancer, Osteoporosis
Additional Keywords : Drug: Tamoxifen
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
[+]

Clinically relevant musculoskeletal symptoms develop in women treated with aromatase inhibitors, leading to treatment discontinuation in a substantial percentage of these patients.Sep 15, 2010

Pubmed Data : Cancer. 2010 Sep 15;116(18):4360-7. PMID: 20549827
Article Published Date : Sep 15, 2010
Study Type : Human Study
Additional Links
Diseases : Drug-Induced Toxicity , Musculoskeletal Abnormalities
Problem Substances : Exemestane, Letrozole (trade name Femera)
[+]

Letrozole decreases estrogen levels at 12 months but not 24 months, reduces bone density, does not reduce mammographic breast density at 12 months and increases IGF-1 (a known carcinogen) at 12 and 24 months in Apr 01, 2010

Pubmed Data : Breast Cancer Res Treat. 2010 Apr;120(2):427-35. Epub 2009 Dec 6. PMID: 19967558
Article Published Date : Apr 01, 2010
Study Type : Human Study
Additional Links
Diseases : Breast Cancer, Insulin-like Growth Factor (IGF): Elevated
Problem Substances : Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
Adverse Pharmacological Actions : Carcinogenic
[+]

Musculoskeletal complaints are exceedingly common (71.5%) in those receiving long-term (6 months or longer) aromatase inhibitor therapy.Feb 01, 2010

Pubmed Data : Breast Cancer Res Treat. 2010 Feb;120(1):127-34. Epub 2009 Dec 25. PMID: 20035381
Article Published Date : Feb 01, 2010
Study Type : Human Study
Additional Links
Diseases : Arthralgia, Arthritis, Breast Cancer, Drug-Induced Toxicity , Musculoskeletal Abnormalities, Myalgias, Polymyalgia Rheumatica, Tendinitis
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
[+]

Musculoskeletal pains in breast cancer patients under third generation AIs can be severe, debilitating and are associated with tenosynovial and joint changes.Jul 01, 2007

Pubmed Data : Breast Cancer Res Treat. 2007 Jul;104(1):87-91. Epub 2006 Oct 24. PMID: 17061044
Article Published Date : Jul 01, 2007
Study Type : Human Study
Additional Links
Diseases : Breast Cancer: Recovery , Musculoskeletal Abnormalities
Problem Substances : Aromatase Inhibitor Drugs, Exemestane, Letrozole (trade name Femera)
[+]

Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia.Oct 01, 2010

Pubmed Data : J Endocrinol. 2010 Oct;207(1):27-34. Epub 2010 Jul 30. PMID: 20675302
Article Published Date : Oct 01, 2010
Study Type : Human Study
Additional Links
Diseases : Bone Diseases, Children: Impaired Growth, Drug-Induced Toxicity , Prostatic Hyperplasia: Benign
Problem Substances : Aromatase Inhibitor Drugs, Letrozole (trade name Femera)
Adverse Pharmacological Actions : Endocrine Disruptor
[+]

The aromatase inhibitor letrozole has endocrine disruptive properties on hypothalamic-pituitary output in normal women.Feb 24, 2011

Pubmed Data : Fertil Steril. 2011 Feb 24. Epub 2011 Feb 24. PMID: 21353673
Article Published Date : Feb 24, 2011
Study Type : Human Study
Additional Links
Diseases : HPA Axis Dysregulation
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Endocrine Disruptor: Pituitary
[+]

The aromatase inhibitors anastrozole, letrozole and exemestane have been associated with skeletal complications, arthralgia, mucuoskeletal pain and sexual dysfunction.Feb 01, 2008

Pubmed Data : Ther Clin Risk Manag. 2008 Feb;4(1):189-204. PMID: 18728707
Article Published Date : Feb 01, 2008
Study Type : Human Study
Additional Links
Problem Substances : Arimidex, Aromatase Inhibitor Drugs, Exemestane, Letrozole (trade name Femera)
[+]

Gestational exposure to doses of letrozole that are equal to or lower than the daily recommended human dose has toxic effects on prenatal development in rats.Aug 01, 2008

Pubmed Data : Hum Reprod. 2008 Aug;23(8):1719-23. Epub 2008 May 15. PMID: 18487213
Article Published Date : Aug 01, 2008
Study Type : Animal Study
Additional Links
Diseases : Birth Defects, Drug-Induced Toxicity , Prenatal Chemical Exposures
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Embryotoxic, Teratogenic
[+]

Letrozole has a toxic effect on the embryos of rats. Nov 01, 2009

Pubmed Data : Hum Reprod. 2009 Nov;24(11):2688-92. Epub 2009 Jul 27. PMID: 19638353
Article Published Date : Nov 01, 2009
Study Type : Animal Study
Additional Links
Diseases : Abortion: Spontaneous, Birth Defects, Prenatal Chemical Exposures
Problem Substances : Letrozole (trade name Femera)
Adverse Pharmacological Actions : Embryotoxic, Teratogenic
[+]

Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole-induced polycystic ovary syndrome.May 09, 2023

Pubmed Data : Phytother Res. 2023 May 10. Epub 2023 May 10. PMID: 37165686
Article Published Date : May 09, 2023
Study Type : Animal Study
Additional Links
Substances : Naringenin
Diseases : Polycystic Ovary Syndrome
Problem Substances : Letrozole (trade name Femera)
[+]

Ocimum kilimandscharicum L. restores ovarian functions in letrozole-induced polycystic ovary syndrome.Jul 07, 2019

Pubmed Data : Life Sci. 2019 Jul 8:116640. Epub 2019 Jul 8. PMID: 31295470
Article Published Date : Jul 07, 2019
Study Type : Animal Study
Additional Links
Substances : African Basil
Diseases : Polycystic Ovary Syndrome
Pharmacological Actions : Insulin Sensitizers
Problem Substances : Letrozole (trade name Femera)

Print Options

Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.
  • Printer-friendly version

Connect with GreenMedInfo